Moderna Inc (NASDAQ:MRNA) shares, rose in value, with the stock price down by -3.55% to the previous day’s close as strong demand from buyers drove the stock to $106.51.
Actively observing the price movement in the last trading, the stock closed the session at $110.43. The value of beta (5-year monthly) was 1.60. Referring to stock’s 52-week performance, its high was $163.24, and the low was $62.55. On the whole, MRNA has fluctuated by 19.67% over the past month.
With the market capitalization of Moderna Inc currently standing at about $40.69 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$3.21, which is expected to increase to -$2.04 for fiscal year -$7.15 and then to about -$5.03 by fiscal year 2025. Data indicates that the EPS growth is expected to be 42.00% in 2025, while the next year’s EPS growth is forecast to be 29.70%.
According to the average forecast, sales growth in current quarter could jump down -83.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $4.21 billion, representing a decrease of -38.60% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MRNA’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MRNA currently trading nearly 11.48% and 6.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.82, while the 7-day volatility ratio is showing 5.96% which for the 30-day chart, stands at 5.24%. Furthermore, Moderna Inc (MRNA)’s beta value is 1.61, and its average true range (ATR) is 5.14.
A comparison of Moderna Inc (MRNA) with its peers suggests the former has fared considerably weaker in the market. MRNA showed an intraday change of -3.55% in last session, and over the past year, it shrunk by -27.99%%.
Data on historical trading for Moderna Inc (NASDAQ:MRNA) indicates that the trading volumes over the past 10 days have averaged 4.55 million and over the past 3 months, they’ve averaged 5.13 million. According to company’s latest data on outstanding shares, there are 382.00 million shares outstanding.
Nearly 12.20% of Moderna Inc’s shares belong to company insiders and institutional investors own 66.00% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 22.11 million shares as on Feb 29, 2024, resulting in a short ratio of 5.38. According to the data, the short interest in Moderna Inc (MRNA) stood at 5.79% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 20.88 million. The stock has risen by 7.10% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MRNA stock heading into the next quarter.
